Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Research and development revenue under collaboration agreement	$ 3,384	$ 3,474
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:InProcessResearchAndDevelopmentMember	us-gaap:InProcessResearchAndDevelopmentMember
Operating expenses:
Research and development	$ 14,343	$ 10,021
General and administrative	6,003	3,173
Total operating expenses	20,346	13,194
Loss from operations	(16,962)	(9,720)
Other income (expense)
Interest income	172	4
Other expense	49
Total other income, net	123	4
Net loss	(16,839)	$ (9,716)
Other comprehensive loss
Unrealized loss on marketable securities	(478)
Total comprehensive loss	$ (478)
Net loss per share:
Net loss per share attributable to common stockholders basic and diluted	$ (0.47)	$ (2.52)
Weighted-average common stocks outstanding, basic and diluted	36,075,407	3,850,264